Moloney Securities Asset Management LLC Has $686,000 Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Moloney Securities Asset Management LLC grew its position in Moderna, Inc. (NASDAQ:MRNA) by 75.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,260 shares of the company’s stock after acquiring an additional 4,419 shares during the quarter. Moloney Securities Asset Management LLC’s holdings in Moderna were worth $686,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of MRNA. Ashton Thomas Private Wealth LLC bought a new stake in shares of Moderna in the 2nd quarter worth approximately $26,000. Cedar Wealth Management LLC lifted its position in shares of Moderna by 45.0% in the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after acquiring an additional 90 shares during the period. Family Firm Inc. bought a new stake in shares of Moderna in the 2nd quarter worth approximately $33,000. Bank & Trust Co bought a new position in shares of Moderna during the 2nd quarter worth approximately $36,000. Finally, Hanseatic Management Services Inc. bought a new position in shares of Moderna during the 2nd quarter worth approximately $48,000. Institutional investors own 75.33% of the company’s stock.

Moderna Stock Down 2.8 %

NASDAQ MRNA opened at $51.81 on Thursday. The stock has a fifty day moving average of $63.00 and a 200-day moving average of $99.97. The stock has a market capitalization of $19.92 billion, a P/E ratio of -3.37 and a beta of 1.69. Moderna, Inc. has a 52 week low of $49.60 and a 52 week high of $170.47. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09.

Insider Activity

In other news, CFO James M. Mock sold 715 shares of Moderna stock in a transaction on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the sale, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the sale, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at $682,754. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO James M. Mock sold 715 shares of Moderna stock in a transaction on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 3,184 shares of company stock valued at $238,531. Company insiders own 15.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Hsbc Global Res upgraded Moderna from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 28th. JPMorgan Chase & Co. cut their target price on Moderna from $70.00 to $59.00 and set an “underweight” rating for the company in a research report on Monday. Deutsche Bank Aktiengesellschaft upgraded Moderna from a “sell” rating to a “hold” rating and cut their target price for the stock from $85.00 to $80.00 in a research report on Wednesday, August 7th. Piper Sandler cut their target price on Moderna from $157.00 to $115.00 and set an “overweight” rating for the company in a research report on Friday, September 13th. Finally, TD Cowen cut their target price on Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a research report on Friday, September 13th. Two analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Moderna currently has a consensus rating of “Hold” and an average price target of $94.00.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.